Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avandia Advisory Committee Re-Review Reflects Well On FDA

Executive Summary

The FDA advisory committee re-review of cardiovascular safety risks with GlaxoSmithKline's Avandia (rosiglitazone) will not end calls from agency critics to create a separate drug safety center. However, the transparency of internal scientific disputes on display at the July 13-14 meeting and the committee's recommendations could take some ammunition away from those who assert the Center for Drug Evaluation and Research has given short shrift to safety issues

Related Content

Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
Anatomy Of The Avandia Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views
FDA, EMA Decisions On Avandia Reflect The Power Of REMS
Behind Closed Doors: FDA Drug Safety Board Will Keep Its Decisions Private
Avandia Advisory Committee Sees New Role For REMS As Research Tool
Avandia Meeting Spurs New Scrutiny Of FDA Conflict-Of-Interest Screening
FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study
Avandia Safety Rhetoric Ramps Up Ahead Of Advisory Committee Review
CDER Offices Go Public With “Fundamental Disagreement” Over Avandia
CDER Offices Go Public With “Fundamental Disagreement” Over Avandia





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts